Here are three more potential causes of paralysis in patients with AIDS:
- Cryptococcal meningitis: The most common fungal infection of the CNS in AIDS patients. Can cause increased intracranial pressure, cranial neuropathies, and spinal cord compression.
- Progressive multifocal leukoencephalopathy (PML): Caused by JC virus reactivation in AIDS patients. Presents with cognitive impairment, visual changes, and sometimes motor deficits. MRI often shows multifocal white matter lesions.
- Vacuolar myelopathy: Caused by HIV itself. Presents with spastic paraparesis. MRI may show T2 hyperintensities in the lateral and posterior columns of the spinal cord. Treat
Module: Pharmacology and Therapeutics III, (Therapeutics part)
Coordinator: Dr. Arwa M. Amin Mostafa
Academic Level: Undergraduate, B.Pharmacy
School: Dubai Pharmacy College
Year of first presented in Class: 2018
This presentation is for Educational purpose. It has no commercial value associated with it.
Contains 17 clinical situations of prolonged fever and discussion of various differential diagnosis based on them. Also gives the key points in the diagnosis of a prototype diagnosis and the usefulness of a relevant investigation modality in identifying these conditions. This power point presentaion is based on the chapter in Harrison's Text Book on Internal Medicine chapter on Fever of Unknown Origin
Module: Pharmacology and Therapeutics III, (Therapeutics part)
Coordinator: Dr. Arwa M. Amin Mostafa
Academic Level: Undergraduate, B.Pharmacy
School: Dubai Pharmacy College
Year of first presented in Class: 2018
This presentation is for Educational purpose. It has no commercial value associated with it.
Contains 17 clinical situations of prolonged fever and discussion of various differential diagnosis based on them. Also gives the key points in the diagnosis of a prototype diagnosis and the usefulness of a relevant investigation modality in identifying these conditions. This power point presentaion is based on the chapter in Harrison's Text Book on Internal Medicine chapter on Fever of Unknown Origin
Clinical Approach To Aseptic Meningitis and Encephalitis
Virology Rotation (R2) , Clinical Microbiology Residency
King Fahd Hospital of The University
23/4/2019
Acute meningoencephalitis Powerpoint presentation.
It comprises of acute meningitis and acute encephalitis, their clinical features, physical assesment, diagnosis and treatment.
Clinical Approach To Aseptic Meningitis and Encephalitis
Virology Rotation (R2) , Clinical Microbiology Residency
King Fahd Hospital of The University
23/4/2019
Acute meningoencephalitis Powerpoint presentation.
It comprises of acute meningitis and acute encephalitis, their clinical features, physical assesment, diagnosis and treatment.
Does CD4 Cell Count Influence CT features of Intracranial Opportunistic Infec...hajikareem00
The number of HIV cases in Malaysia in people aged 15 to 49 are 80,000 with its current rate of doubling every three years. In Malaysia, opportunistic infections such as Cryptococcus are found to be associated with advanced HIV infection. In predicting this, a useful guide is by monitoring the CD4 + T-Lymphocyte count. Neuroimaging plays a crucial role in establishing early intracranial involvement. In malaysia 5 oppurtunity infections: TB, PCP, toxoenceph, crypto mening,Bact pneumonia (Nissapatorn 2003)
According to Malaysia Ministry of Health Report year 2004; males remain the majority (93%) of reported HIV and AIDS cases (91%) within age group of 20 to 39 years. Malay teenagers and males involved in the drug addiction Another study in KL: most frequent routes of transmission were sexual contact (78.5%), followed by IDUs (30%), All females patients included in this study were a former wife to an intravenous drug users in which the virus transmission occurs through unprotected sexual relationship. This is due to poor knowledge regarding the relationship between drug addiction with HIV transmission and various routes of HIV/AIDS transmission in the community. Ignorance and being a naïve wife to those husbands involved with drug addiction also further increase HIV transmission.
The objective of this study is to identify the association between CD4 count with the site and type of intracranial lesions of opportunistic infections in HIV/AIDS patients.
Results of our study: All male patients were IV drug users. Late stage of HIV infection with a CD4 count <200><50.>< 50cells/µl presenting with non focal neurological symptoms of headache or altered behaviour. The CT findings were normal in 5 scans, cerebral atrophy in 1 scan and the rest had mass lesions.
Among 56 patients serological study for toxoplasmosis was done in 41 patients. Where by, 7 and 49 patients were in middle and late stage of the disease process respectively. This contribute to the high percentage of late stage patients with focal lesion as compared to those patients in middle stage of their illness (n=35 (71.4%) versus n=3 (42.9%) respectively).
No statistically significant correlation observed between intracranial lesions with clinical stage of disease in this study
--Professor Madya Dr. Hj. M. ABDUL KAREEM. USM, KUBANG KERIAN, KOTA BHARU, MALAYSIA
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxoplasmosis .
Updated guide lines for treatment of Toxoplasmosis in HIV patient accodring to DHHS guide lines 2013 and other recommendations
This slides gives a basic understanding of urinary tract infections to a general physician, it's definition,epidemiology, causes, risk factors, clinical features, investigations, treatment and prevention.
It also helps a physician to have the ability on to mange urinary tract infections in paediatric patients.
AIDS is caused by the human immunodeficiency virus (HIV).
The primary mechanism is to infect a particular subset of T lymphocyte called CD4 cells.
Over the time HIV decreases the number of CD4 cells.
As a person’s CD4 count drops, they become at increasing risk of developing opportunistic infections.
HIV, by itself, does not harm the patient.
HIV harms by destroying cell-mediated immunity
The infections that develop are what harm patients.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
HIV Opportunistic Infections Iralu
1. HIV Opportunistic Infection Update
Jonathan Vilasier Iralu, MD, FACP
Indian Health Service Chief Clinical Consultant for
Infectious Diseases
2. Case
• A 47 year old woman with AIDS (CD4 37, V.L.
90,000) presents to your clinic with fever of 103
daily for 4 weeks. She has had watery diarrhea for 6
weeks. Physical exam shows muscle wasting and
splenomegaly. A CXR is normal.
– What is the differential diagnosis?
– What should you do now?
7. M. avium Review
• Slow growing Acid-Fast Bacillus seen when CD4 <50
• Patients present with fever, sweats and chronic diarrhea.
• Cachexia, hepatosplenomegaly and lymphadenopathy are
often seen on physical exam.
• Pancytopenia and elevated alkaline phosphatase are
8. MAC Diagnostics
• Bactec Blood cultures are the test of choice.
– Positive in 7-10 days
• Other cultures helpful but invasive:
– Bone Marrow : Positive in 17 of 30 blood culture positive
cases
– Gut biopsy useful to document mucosal invasion
• Sputum and stool Cx are not reliable.
• CT Abdomen : Adenopathy seen in 42% of cases
9. MAC Therapeutics
• Basic Therapy
– Clarithromycin 500 mg po BID
• Plus
– Ethambutol 15-20 mg/kg po QD
10. MAC Therapeutics
• Treatment Options:
– Addition of Rifabutin 300 to 450 mg po QD is optional if
> 100 organisms per ml or HAART ineffective.
– Azithromycin: if GI intolerance or drug interactions
– Treat until CD4 > 200 for 6 months and cultures negative
for 12 months
11. MAC Therapeutics
• Salvage Regimen
– Amikacin 10 mg/kg iv QD
– plus either
– Ciprofloxacin 500 mg po BID
– or
– Rifabutin 300-450 mg po QD
12. MAC Prevention
• Start Azithromycin 1200 mg po weekly if CD4 < 50
• Stop Prophylaxis if CD4 > 100 for 3 months
13. HIV/AIDS Update
Case
• A 27 year old male with a history of IDU now notes 5
days of non-productive cough. He has lost 3 pounds
since the last visit. Physical exam is notable for
cachexia. When he walks around the clinic his
oxygen saturation drops to 84%.
– What is the differential diagnosis?
– What should you do now?
15. NAIHS HIV/AIDS
Initial evaluation of infiltrates
• Routine Gram stain and culture
• Blood cultures
• Sputum AFB smear and culture X 3
• Induced sputum for PCP immunofluorescence
16. NAIHS HIV/AIDS
Pulmonary Infiltrate Therapy
• Typical pneumonia, CD4 > 500
• -Third generation cephalosporin plus a macrolide
• Atypical pneumonia, CD4 < 500
• Trimethoprim/Sulfa plus a cephalosporin plus a
macrolide
17. NAIHS HIV/AIDS
Further Infiltrate evaluation
• What to do next if routine tests are negative
– Bronchoalveolar Lavage
– Transbronchial lung biopsy
– Transcutaneous lung biopsy
18. PCP Pneumonia
• Pneumocystis jiroveci is the causative agent
• Still called “PCP”
• Classified now as a fungus
– Cell wall has Beta-D-glucan
– Ubiquitous in the environment
– Can be transmitted from one immunocompromised host
to another.
22. Other PCP diagnostics
• Beta-D Glucan Assay (Watanabe, Clin Infect Dis 2009):
– 96% sensitivity
– 88% specificity
• S-adenosylmethionine assay
– Required for growth of PCP
– Levels are depleted in patients with PCP
– Requires HPLC device
23. PCP Treatment (21 days)
• Parenteral Regimens
– Trimethoprim-Sulfa: 5 mg/kg IV q 8h for 21 days
– Pentamidine 4 mg/kg IV daily for 21 days
• Oral Regimens
– Tmp/SMZ DS 2 po tid
– TMP 5 mg/kg po tid plus Dapsone 100 mg po qday
– Clinda 450 mg po qid plus Primaquine 15 mg po qday
– Atovaquone 750 mg po bid
24. PCP Adjunctive Rx
• Give Steroids if
– A-a gradient > 35mm or
– pAO2 < 70mm
• Prednisone
– 40 mg po bid for 5 days then
– 40 mg po daily for 5 days then
– 20 mg po daily for 21 days
25. PCP Prophylaxis
• TMP/SMZ DS 1 po daily or TIW
• Dapsone 100 mg po daily
• Atovaquone 750 mg po bid
• Pentamidine neb 300 mg monthly
• Stop when CD4 count is > 200 for 3 months
26. HIV/AIDS Update
Case
• A 53 year old woman with HIV now has diarrhea.
She was treated with ZDV/3TC/NFV originally but
now is on a second regimen including
TDF/FTC/ATZ/rtv. She notes 6 weeks of watery stools
without fever or blood
– What is the differential diagnosis?
– What should you do now?
29. NAIHS HIV/AIDS
Diarrhea work up
• Initial evaluation
– CBC, electrolytes, BUN, Creatinine, LFTS
– Routine stool culture
– Clostridium difficile toxin assay
– Stool Ova and Parasites exam
– Stool Trichrome stain
– Stool Modified AFB Stain
30. NAIHS HIV/AIDS
Diarrhea workup
• Further workup
– Upper endoscopy with small bowel Bx.
– Colonoscopy with Bx.
31. Microsporidiosis
• Spore forming protozoan with fungal characteristics
• Ubiquitous in the environment
• 1-2 microns in size
• Two species
– Enterocytozoan bieuneusi- major cause of diarrhea
– Encephalitozoan cuniculi and hellem- disseminate
• Distort small bowel villous architecture
32. Microsporidiosis
• Clinical syndrome:
– Profuse watery diarrhea
– Median CD4 is 20
– Biliary, lung, corneal, renal disease and encephalitis all
occur
• Diagnosis
– Modified trichrome stain
33. Microsporidiosis
• Treatment
– Albendazole 400 mg po bid for Encephalocytozoan sp
– No reliable Rx for Enterocytozoan bienusi
34. Cytomegalovirus colitis
• CMV is a herpesvirus that infects latently
• AIDS patients affected when CD4 <50
• CMV viremia is a risk factor for subsequent invasion
35. Cytomegalovirus
• Clinical Manifestations
– Esophagitis with odynophagia, fever and nausea
– Gastritis with epigastric pain but rarely bleeds
– Enteritis of small bowel: pain and diarrhea
– Colitis: fever, weight loss, watery diarrhea and
hemorrhage
36. Cytomegalovirus colitis
• Diagnosis:
– PCR of blood
– Biopsy: cytomegalic cells with eosinophilic intranuclear
and basophilic cytoplasmic inclusions.
37. CMV Treatment
• Gancylovir induction 5 mg/kg IV q 12 hrs then Valgancyclovir
900 mg po bid when better for 3-6 weeks
• Maintenance therapy with daily VGC for relapsed cases
• Support WBC with G-CSF
• Foscarnet is usually reserved for salvage therapy
38. Case presentation
• A 51 year old man with HIV develops sudden visual
impairment in the right eye. He has had low grade
fevers for a few weeks. His last CD4 count was 97
and the viral load is > 100,000.
39. CMV Retinitis
• Affect 47% of patients with CD4 < 50
• If no HAART is given, median time to progression is
47-104 days.
• Median time to death was 0.65 years in the pre
HAART era.
41. CMV Retinitis
• Examination
– Fluffy lesions near vessels with hemorrhage
• Fulminant (hemorrhagic
• Indolent (non hemorrhagic)
• Mixed
– Retinal detachment
– Immune Reconstitution uveitis
• Vitreous involvement is pathognomonic for IRIS
42. CMV Retinitis
Treatment
– First line:
• Valganciclovir 900 mg po bid for 14-21 days then 900 mg po
daily until CD4 >100 for 3-6 months
– If <1500 microns from fovea or near optic head
• IV gancyclovir
• Gancyclovir ocular implant or injection
– Other drugs
• Foscarnet
• Cidofovir
44. HIV/AIDS Update Case
• A 45 year old man with AIDS (CD4 85) now has a
headache of three weeks duration. His friends say he
is confused. Your neurologic exam reveals a left
pronator drift.
– What is the differential diagnosis?
– What should you do now?
45. Differential for paralysis in AIDS
• Brain • Upper motor neuron
– Toxoplasmosis – Vacuolar myelopathy
– TB
– Lymphoma
– Lymphoma
– TB – Epidural abscess
– Cryptococcosis • Lower Motor Neuron
– Nocardia – CIDP
– Brain abscess – Mononeuritis multiplex
– PML – CMV polyradiculopathy
46. NAIHS HIV/AIDS
Evaluation for paralysis in AIDS
• Initial work-up
– Head CT scan
– Lumbar Puncture
• Further work-up
– MRI of brain or spine for upper motor neuron Dz
– NCV/EMG for lower motor neuron Dz
47. Brain Mass Lesion
• Three major clinical entities
– Toxoplasmosis:
• More often multiple
– Primary CNS Lymphoma (PCNSL)
• Half the time solitary
• If > 4cm, PCNSL is more likely
– Progressive Multifocal Leukoencephalopathy
• Usually non-enhancing
• Will enhance if IRIS is present after institution of ART
48. Brain Mass Lesion
Evaluation
• If no mass effect, proceed with LP and treat
– Toxo +)toxoplasmosis
– EBV (+)CNS lymphoma
– JC virus (+)PML
• If mass effect and herniating, proceed with brain
biopsy
• If mass effect and not herniating and Toxo Ab
positivea trial of anti toxo Rx
49. Toxoplasmosis
• Caused by Toxoplasma gondi a protozoan
• Causes latent infection, reactivates when CD4 < 100
• Acquired through exposure to cats and eating poorly
cooked meats
51. Toxoplasmosis
• Diagnosis
– Serology
– CT or MRI with contrast
– SPECT or PET: (decreased thallium uptake and glucose
use with toxo)
– Biopsy: 3-4% morbidity rate
– PCR: 50-98% sensitive, 96-100% specific
52. Toxoplasmosis
• Treatment
– Pyramethamine 200 mg po x1 then 50-75 mg po daily
– Sulfadiazine 1-1.5 gm po qid
– Leukovorin 10-25 mg po daily
– Clindamycin is substituted for sulfdiazine if sulfa allergic
53. Three more paralysis syndromes
• Vacuolar myelopathy: Upper motor neuron
– spastic
– hyper-reflexic
– no pleocytosis
– normal glucose
54. Three more paralysis syndromes
• Chronic Inflammatory Demyelinating
Polyneuropathy
– Looks like Guillain Barre Syndrome
• Flaccid
• Areflexic
• High CSF protein is the hallmark
– Pretty good prognosis with treatment
55. Three more paralysis syndromes, contd
• CMV Polyradiculopathy
– Flaccid
– Areflexic
– Polys in CSF suggesting bacterial meningitis
– Low glucose suggesting bacterial meningitis
• CMV Ventriculoencephalitis
– Polys in CSF and low glucose
– Periventricular enhancement
56. Three more paralysis syndromes
• Treatment
– Vacuolar Myelopathy: ART
– CIDP: ART plus steroids and plasmapheresis
– CMV Polyradiculopathy: ganciclovir +/- foscarnet